Aadi Bioscience Rockets 72% on Key Updates

Seeking AlphaDec 20 02:37 ET

KAKEN PHARMACEUTICAL To Go Ex-Dividend On March 28th, 2025 With 0.66 USD Dividend Per Share

Moomoo NewsNov 8 19:45 ET

KAKEN PHARMACEUTICAL To Go Ex-Dividend On September 27th, 2024 With 0.66 USD Dividend Per Share And 0.352 USD Special Dividend Per Share

Moomoo NewsJul 9 19:40 ET

Kaken Pharmaceutical Sees FY Net Y5.60B

Dow JonesMay 14 00:30 ET

Transfer of the rights of “Melislon” and “Mionar” in Japan to Kinkaku Pharmaceutical

For printing 2024/3/29, Eisai Co., Ltd. (Headquarters: Tokyo; Representative Executive Officer and CEO: Haruo Naito) is pleased to announce that it has now signed an agreement to transfer domestic rights to the vertigo and balance disorder treatment agent “Melisone” (generic name: betahistine mesylate) and the muscle tone improving agent “Mional” (generic name: eperisone hydrochloride) to Kagaku Pharmaceutical Co., Ltd. (Headquarters: Tokyo, hereinafter referred to as Kaken Pharmaceutical). “Merislon” and “Mionard” are those in Japan

EisaiMar 28 11:00 ET

Kaken Pharmaceutical 1H Net Y4.07B Vs Net Y5.96B

Dow JonesNov 7, 2023 23:30 ET